Literature DB >> 18362186

Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.

J W C Alffenaar, P M de Vries, G J Luijckx, D van Soolingen, T S van der Werf, R van Altena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18362186      PMCID： PMC2415813          DOI： 10.1128/AAC.01637-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  14 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

2.  In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; M López; G Royo
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

3.  Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration.

Authors:  H Stass; D Kubitza; U Schühly
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results.

Authors:  G Valerio; P Bracciale; V Manisco; M Quitadamo; G Legari; S Bellanova
Journal:  J Chemother       Date:  2003-02       Impact factor: 1.714

5.  Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.

Authors:  Tetsuyuki Yoshimatsu; Eric Nuermberger; Sandeep Tyagi; Richard Chaisson; William Bishai; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.

Authors:  William J Burman; Stefan Goldberg; John L Johnson; Grace Muzanye; Melissa Engle; Ann W Mosher; Shurjeel Choudhri; Charles L Daley; Sonal S Munsiff; Zhen Zhao; Andrew Vernon; Richard E Chaisson
Journal:  Am J Respir Crit Care Med       Date:  2006-05-04       Impact factor: 21.405

7.  Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.

Authors:  V Rodriguez-Cerrato; C C McCoig; I C Michelow; F Ghaffar; H S Jafri; R D Hardy; C Patel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

Authors:  H M J Nijland; R Ruslami; A Juwono Suroto; D M Burger; B Alisjahbana; R van Crevel; R E Aarnoutse
Journal:  Clin Infect Dis       Date:  2007-09-04       Impact factor: 9.079

9.  Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs.

Authors:  Luigi Ruffo Codecasa; Giovanni Ferrara; Maurizio Ferrarese; Maria Antonietta Morandi; Valeria Penati; Carla Lacchini; Patrizia Vaccarino; Giovanni Battista Migliori
Journal:  Respir Med       Date:  2006-02-15       Impact factor: 3.415

10.  Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.

Authors:  C Ostergaard; T K Sørensen; J D Knudsen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
View more
  5 in total

1.  Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.

Authors:  Anushka Naidoo; Veron Ramsuran; Maxwell Chirehwa; Paolo Denti; Helen McIlleron; Kogieleum Naidoo; Nonhlanhla Yende-Zuma; Ravesh Singh; Sinaye Ngcapu; Mamoonah Chaudhry; Michael S Pepper; Nesri Padayatchi
Journal:  Pharmacogenomics       Date:  2017-12-06       Impact factor: 2.533

2.  Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid.

Authors:  Marija Djukic; Martin Munz; Fritz Sörgel; Ulrike Holzgrabe; Helmut Eiffert; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

Review 3.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

4.  Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Authors:  Guy E Thwaites; Sujata M Bhavnani; Tran Thi Hong Chau; Jeffrey P Hammel; M Estée Török; Scott A Van Wart; Pham Phuong Mai; Daniel K Reynolds; Maxine Caws; Nguyen Thi Dung; Tran Tinh Hien; Robert Kulawy; Jeremy Farrar; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

Review 5.  Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment.

Authors:  Divine C Nwafor; Allison L Brichacek; Afroz S Mohammad; Jessica Griffith; Brandon P Lucke-Wold; Stanley A Benkovic; Werner J Geldenhuys; Paul R Lockman; Candice M Brown
Journal:  J Cent Nerv Syst Dis       Date:  2019-04-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.